Join to view full profile
22 S Greene StBaltimore, MD 21201
Phone+1 410-328-5793
Fax+1 410-328-0248
Dr. Doyle is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MarylandResidency, Internal Medicine, 1978 - 1981
University of Maryland School of MedicineClass of 1978
Certifications & Licensure
MD State Medical License 1979 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 107 citationsA phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, Shengjie Wu, Azra H. Ligon
Neuro-Oncology. 2021-10-01 - 1 citationsPhase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.Joleen M. Hubbard, Jun Yin, Erin L. Schenk, Rui Qin, Joel M. Reid
Investigational New Drugs. 2021-09-13 - 72 citationsEffect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.Kevin Kalinsky, Fangxin Hong, Carolyn K. McCourt, Jasgit C. Sachdev, Edith P. Mitchell
JAMA Oncology. 2021-02-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:










